Legius syndrome is a rare autosomal dominant genetic disorder characterized by multiple café au lait spots, specific facial dysmorphia, and an increased risk of developing tumors. This pathology belongs to the group of neurofibromatosis-like disorders and is often accompanied by dysfunction of the central nervous system, including mental retardation of varying severity. The clinical picture of the disease is characterized by significant polymorphism of manifestations, which complicates timely diagnosis and requires a comprehensive approach to examining patients.
History of the disease and interesting historical facts
The initial description of Legius syndrome was presented in 2007 by Belgian researchers led by Professor Jean-Pierre Freeman. Interestingly, for a long time this condition was erroneously classified as neurofibromatosis type I due to the similarity of some clinical manifestations. “The discovery of a mutation in the SPRED1 gene was a turning point in understanding the nature of this disease,” the authors of the original publication note. The first scientific papers showed that the disease is much more common than previously thought, but simply remained undiagnosed.
Epidemiology (statistics of disease occurrence)
According to international studies, the prevalence of Legius syndrome is approximately 1 case per 80,000 newborns. However, the actual frequency may be higher due to the difficulty of diagnosis. According to statistics:
- Approximately 3% patients with clinical picture of neurofibromatosis type I actually have Legius syndrome
- The incidence does not have a pronounced gender predisposition.
- The highest frequency of detection is observed in populations of European origin
Genetic predisposition to the disease (involved genes and mutations)
The main cause of Legius syndrome is mutations in the SPRED1 gene, located on chromosome 15q14. This gene encodes a protein involved in the regulation of the RAS/MAPK signaling pathway. The most common types of mutations include:
- Nonsense mutations
- Deletions of various sizes
- Missense mutations
- Splicing mutations
“About 60-70% familial cases can be explained by mutations in the SPRED1 gene,” current research suggests. The remaining cases may be due to mutations in other genes or mosaicism.
Risk factors for the development of this disease
In addition to genetic predisposition, there are additional factors that may influence the expression of the disease:
- Age of parents at conception (especially over 35 years)
- Contact with mutagenic substances during pregnancy
- Radiation exposure
- Certain medications taken during pregnancy
“The environment can modulate the degree to which mutations occur,” toxicologists point out in their research.
Diagnosis of this disease
The diagnostic process includes several key stages:
- Main symptoms: multiple coffee stains, facial dysmorphia, mental retardation
- Laboratory tests: SPRED1 gene sequencing, MLPA analysis
- Radiological examinations: MRI of the brain, ultrasound of internal organs
- Other types of diagnostics: dermatoscopy, ophthalmological examination
- Differential diagnosis: neurofibromatosis type I, Watson syndrome, Noonan syndrome
Treatment
The therapeutic approach includes a comprehensive impact:
- General treatment: lifestyle correction, diet therapy
- Pharmacological treatment: symptomatic therapy
- Surgical treatment: removal of tumors if necessary
- Other types of treatment: psychological and pedagogical correction, rehabilitation programs
List of drugs used to treat this disease
- CNS stimulants
- Nootropic drugs
- Antioxidants
- Drugs that improve brain metabolism
- Symptomatic remedies
Disease monitoring
Regular monitoring includes the following steps:
- Annual examinations by a neurologist and dermatologist
- Control MRI every 2-3 years
- Assessment of neuropsychological development
- Monitoring of possible complications: tumor processes, endocrine disorders
“Early detection of complications significantly improves the prognosis,” experts emphasize.
Age-related features of the disease
Clinical manifestations may vary depending on age:
- In children: predominantly cutaneous manifestations and developmental delays
- In adolescents: increased cognitive impairment
- In adults: the risk of developing tumors increases
Questions and Answers
- How often should I get checked? An annual comprehensive examination with additional studies as indicated is recommended.
- Is it possible to prevent the development of complications? Yes, early diagnosis and regular monitoring help minimize risks.
- How effective is the treatment? Therapy is aimed at correcting symptoms and improving quality of life.
- What is the prognosis for this disease? With adequate monitoring, the prognosis is relatively favorable.
- Is the disease hereditary? The disease has an autosomal dominant type of inheritance.
Advice from Dr. Oleg Korzhikov
In my practice I often encounter the following questions:
- How to prepare for genetic testing? Before the test, it is important to consult with a geneticist and receive detailed information about the procedure.
- What to do at the first signs of illness? It is necessary to immediately contact a specialist for a comprehensive diagnosis.
- How to organize life with such a diagnosis? It is important to create a supportive environment, undergo regular check-ups and follow your doctor's recommendations.
“The main thing is timely diagnosis and the right approach to treatment,” emphasizes Dr. Korzhikov.
